<a href="https://laohu8.com/S/MLTX">MoonLake Immunotherapeutics</a> reports third quarter 2025 results and announces new clinical trial data
MoonLake Immunotherapeutics reported cash, cash equivalents, and short-term marketable debt securities of $380.5 million as of September 30, 2025. The company projects that existing funds, combined with a previously announced debt facility, will be sufficient to finance operating expenses and capital expenditures into the second half of 2027. Research and development expenses for the third quarter were $60.6 million, up from $49.8 million in the previous quarter, primarily due to increased spending on contract research, manufacturing organizations, consulting, and personnel costs related to clinical trials and preparation for a planned BLA submission for sonelokimab in the third quarter of 2026. General and administrative expenses were $10.8 million, similar to the $10.9 million reported in the prior quarter. Key business developments included reporting positive results from the Phase 2 LEDA trial of sonelokimab in palmoplantar pustulosis and interim data from VELA-1, VELA-2, and VELA-TEEN trials in hidradenitis suppurativa, along with scheduling a Type B FDA meeting for December 2025 to discuss the clinical evidence for a potential BLA submission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137112-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.